Mirtapil (Mirtazapine)

Mirtazapine, the active ingredient in Mirtapil, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and may improve mood, sleep, and appetite, and overall functioning.

GNH USA supplies Mirtapil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards, provides batch‑specific certificates of analysis, and offers reliable logistics for cross‑border procurement.

Mirtazapine is indicated for depressive disorders and related conditions, acting on serotonergic and noradrenergic pathways.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients. - Depressive episodes in bipolar disorder: alleviates depressive phase when used under specialist supervision. - Anxiety symptoms associated with depression: helps lessen anxiety and improves sleep quality in affected individuals.

Mirtazapine may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior, especially early in treatment

When prescribing mirtazapine, clinicians should observe several precautionary measures to ensure safe use.

- Monitor weight: regular assessment due to risk of weight gain. - Assess for suicidal ideation: especially during initial weeks or dose changes. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Review concomitant CNS depressants: risk of enhanced sedation. - Store at room temperature: keep in original packaging, protect from moisture.

Mirtazapine interacts with several drug classes; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs): potential serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may increase mirtazapine plasma levels. - Antihypertensive agents: possible additive blood‑pressure lowering effect. - Carbamazepine: may reduce mirtazapine exposure and efficacy.